Rentschler Biopharma expands production of highly complex antibodies at its German site


DGAP-News: Rentschler Biopharma SE / Keyword (s): Miscellaneous
06/30/2021 / 10:00
The issuer is solely responsible for the content of this advertisement.

Rentschler Biopharma expands production of highly complex antibodies at its German site

Laupheim, Germany, June 30, 2021 – Antibody therapies have become an integral part of the treatment of serious and rare diseases. “It is all the more important that we have a high level of expertise in drug development as well as in the development of bioprocesses and the production of therapeutic antibodies,” said Dr Frank Mathias, CEO of Rentschler Biopharma SE, on the occasion of the presentation of the annual industry report “Medical biotechnology in Germany 2021” by Boston Consulting Group (BCG) and vfa bio, the German industry association for biotechnology companies based on the research, which took place yesterday in Berlin.

While Germany has secured an impressive second place * behind the United States in terms of the number of manufactured biopharmaceutical active ingredients approved in the EU, the country lags behind in a global production capacity comparison: while Germany reached third place in 2018, it is only ranked fifth in 2021. Rentschler Biopharma is expanding its production capacity by 2,000 liters of bioreactor.

“For most of the biopharmaceuticals currently in development, this size of bioreactor provides maximum flexibility for manufacturing on a clinical and commercial scale, making it the optimal platform for our business at Rentschler Biopharma,” explained the Dr Mathias. “We focus on supporting our customers in the development of very complex molecules, by manufacturing them in complete safety and according to the highest quality standards. We thus contribute significantly to the availability of life-saving treatments.

Producing over 110 different therapeutic protein formats, including monoclonal and multispecific antibodies as well as antibody derivatives, Rentschler Biopharma has extensive development and production know-how in this pioneering technology. The central role of antibodies in modern healthcare for treating serious or chronic diseases is also reflected in the number of molecules approved at the end of 2020: according to the Biotech report, almost a third of newly approved compounds in Germany were antibodies. This technological platform will continue to gain in importance in the years to come: Representing 65% of all candidates for clinical development, recombinant antibodies represent the majority of biopharmaceuticals in clinical development.

“Looking at the compounds currently in development, the antibodies approved to date, and the experience gained during the pandemic and before with complex global value chains, we need to ensure that patients with serious illnesses have optimal access to innovative therapies. This is where Germany should see its great potential, invest more and continue to play a leading role in the world, ”said Dr Mathias, explaining the company’s plan to use the new capability of the bioreactor. 2000 liters to produce new therapies using antibodies or other active ingredients against serious or rare diseases. diseases.

In addition to process development and production on behalf of clients, Rentschler Biopharma also offers advisory services for new drug development, from cell line selection to regulatory processes, based on decades of expertise and knowledge. many projects completed. Rentschler Biopharma is thus an experienced partner for young and established companies.

* Centrally approved biopharmaceutical production sites in the EU by number of active ingredients – USA: 102, Europe, incl. Switzerland and United Kingdom: 165, of which Germany as market leader: 44.

About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing (CDMO) organization focused exclusively on customer projects. The company offers process development and manufacturing of biopharmaceuticals and related consulting activities, including project management and regulatory support. The high quality of Rentschler Biopharma is proven by its long experience and excellence as a solution partner for its customers. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at every stage of development and manufacturing. In order to offer the best development of formulations throughout the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family business of approximately 1,000 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, United States. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapy, Rentschler ATMP Ltd.

For more information, please visit Follow Rentschler Biopharma on LinkedIn and Facebook.


Rentschler Biopharma SE
Dr Cora Kaiser
Senior Director of Corporate Communications
Phone: + 49-7392-701-874
[email protected]

Media inquiries:

MC Services SA
Eva bauer
Phone: + 49-89-210228-0
[email protected]
Laurie Doyle
Phone: + 1-339-832-0752

06/30/2021 Distribution of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on

Source link


About Author

Leave A Reply